| Drug ID: | Drug12 |
|---|---|
| Drug Name: | Caffeine |
| CID: | 2519 |
| DrugBank ID: | DB00201 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT03358706, , NCT02760615 |
| Molecular Formula: | C8H10N4O2 |
| Molecular Weight: | 194.19 g/mol |
| Isomeric SMILES: | CN1C=NC2=C1C(=O)N(C(=O)N2C)C |
| Synonyms: | caffeine; 58-08-2; Guaranine; 1,3,7-Trimethylxanthine; Methyltheobromine; Theine; Thein; Cafeina; Koffein; Mateina |
| Phase 0: | 18 |
| Phase 1: | 110 |
| Phase 2: | 38 |
| Phase 3: | 45 |
| Phase 4: | 39 |
| Description: | A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes smooth muscle, stimulates cardiac muscle, stimulates diuresis, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide phosphodiesterases, antagonism of adenosine receptors, and modulation of intracellular calcium handling. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt100 | 2519 | Caffeine | 5142 | PDE4B | Homo sapiens (human) | None | |
| dt101 | 2519 | Caffeine | 747 | DAGLA | Homo sapiens (human) | Activator | |
| dt102 | 2519 | Caffeine | 134 | ADORA1 | Homo sapiens (human) | Antagonist | |
| dt103 | 2519 | Caffeine | 4907 | NT5E | Homo sapiens (human) | 37713619 | Inhibitor |
| dt104 | 2519 | Caffeine | 135 | ADORA2A | Homo sapiens (human) | Antagonist | |
| dt105 | 2519 | Caffeine | 136 | ADORA2B | Homo sapiens (human) | 20164566 | Antagonist |
| dt106 | 2519 | Caffeine | 140 | ADORA3 | Homo sapiens (human) | 20164566 | Antagonist |
| dt107 | 2519 | Caffeine | 5144 | PDE4D | Homo sapiens (human) | Inhibitor | |
| dt108 | 2519 | Caffeine | 5140 | PDE3B | Homo sapiens (human) | Inhibitor | |
| dt109 | 2519 | Caffeine | 8654 | PDE5A | Homo sapiens (human) | Inhibitor |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT03358706 | A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis | PHASE1 | TERMINATED | Janssen Research & Development, LLC | Crohn Disease|Ulcerative Colitis | DRUG: Ustekinumab IV Infusion|DRUG: Ustekinumab S… | Details |
| NCT02760615 | Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study | PHASE4 | WITHDRAWN | Takeda | Colitis, Ulcerative|Crohn Disease | DRUG: Caffeine|DRUG: Losartan|DRUG: Omeprazole|DR… | Details |
| NCT05707429 | Sexual Function and Quality of Life Among Patients Suffering From Inflammatory Bowel Disease(Inactive Stage) | NULL | COMPLETED | Assiut University | Sexual Function Disturbances|Inflammatory Bowel D… | OTHER: The Arabic version of The International In… | Details |
| NCT05706038 | Impact of Adalimumab Withdrawal or Continuation on Severity of COVID-19 and Risk of IMID Relapse | NULL | COMPLETED | IRCCS San Raffaele | Inflammatory Bowel Diseases|Rheumatic Disorder | DRUG: Adalimumab | Details |
| NCT05687474 | Baby Detect : Genomic Newborn Screening | NULL | COMPLETED | Centre Hospitalier Universitaire de Liege | Congenital Adrenal Hyperplasia|Familial Hyperinsu… | None | Details |
| NCT05668104 | Jing Si Herbal Tea for Long-Coronavirus Disease(COVID) Gut-brain Interaction | NA | COMPLETED | Buddhist Tzu Chi General Hospital | Healthy Subjects|COVID-19 Pneumonia|Irritable Bow… | DIETARY_SUPPLEMENT: Jing Si Herbal Tea Liquid Pac… | Details |
| NCT05643534 | Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years | PHASE3 | RECRUITING | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | DRUG: Tenapanor 50 MG|DRUG: Tenapanor 25 mg bid|D… | Details |
| NCT05626023 | A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease | PHASE1|PHASE2 | COMPLETED | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Perianal Fistula|Crohn's Disease | DRUG: Human TH-SC01 cell injection | Details |
| NCT05588843 | Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis | PHASE2 | ACTIVE_NOT_RECRUITING | Sanofi | Colitis Ulcerative | DRUG: SAR443122|DRUG: Placebo | Details |
| NCT05584735 | Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine | NULL | COMPLETED | University of Wisconsin, Madison | Inflammatory Bowel Diseases | BIOLOGICAL: Influenza vaccine|BIOLOGICAL: COVID-1… | Details |
| NCT05573685 | Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training | NA | COMPLETED | Click Therapeutics, Inc. | Rheumatoid Arthritis|Diabetic Neuropathy|Fibromya… | DEVICE: DiNaMo Study App|DEVICE: Placebo App | Details |
| NCT05542355 | EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease | PHASE1 | TERMINATED | Exeliom Biosciences | Crohn Disease | DRUG: EXL01|DRUG: Placebo|OTHER: SoC corticostero… | Details |
| NCT05536440 | A Study to Learn About Study Medicine Called PF-07261271 in Healthy People | PHASE1 | COMPLETED | Pfizer | Healthy | DRUG: PF-07261271|DRUG: Placebo | Details |
| NCT05528510 | A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | PHASE3 | ACTIVE_NOT_RECRUITING | Janssen Research & Development, LLC | Colitis, Ulcerative | DRUG: Guselkumab Dose 1|DRUG: Guselkumab Dose 2|D… | Details |
| NCT07161297 | Remimazolam for Colonoscopy in IBD Patients | PHASE4 | NOT_YET_RECRUITING | Humanitas Clinical and Research Center | IBD (Inflammatory Bowel Disease) | DRUG: Intravenous remimazolam (5 mg initially, wi… | Details |
| NCT05507931 | Broccoli Sprouts for Mild Ulcerative Colitis | NA | COMPLETED | University of Michigan | Ulcerative Colitis|Ulcerative Colitis Chronic Mild | DIETARY_SUPPLEMENT: 1 Serving of broccoli sprouts… | Details |
| NCT05507203 | ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 | PHASE3 | COMPLETED | Abivax S.A. | Ulcerative Colitis | DRUG: ABX464|DRUG: Placebo | Details |
| NCT07156929 | Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation | NA | COMPLETED | University Hospital Schleswig-Holstein | Respiratory Infection (for Example, Pneumonia, Br… | DIETARY_SUPPLEMENT: Controlled-ileocolonic-releas… | Details |
| NCT05466890 | Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) | PHASE2 | ACTIVE_NOT_RECRUITING | Palatin Technologies, Inc | Ulcerative Colitis|Ulcerative Colitis Acute|Ulcer… | DRUG: PL8177 Placebo|DRUG: PL8177 | Details |
| NCT05389709 | A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting | NULL | COMPLETED | Bayer | Functional Gastrointestinal Disorders Such as Irr… | DRUG: Iberogast (STW5-II, BAY98-7410) | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
Does caffeine have a double-edged sword role in inflammation and carcinogenesis…
PMID: 37072923
Year: 2023
Relationship Type:
Association
Score: 7.5
Caffeine (1,3,7-trimethylxanthine, also abbreviated to CAF) is a natural chemical with stimulant effects and is commonly included in many drinks and …
Association Between Caffeine Intake and Bowel Habits and Inflammatory Bowel Dis…
PMID: 40600201
Year: 2025
Relationship Type:
Association
Score: 6.5
BACKGROUND: The effect of caffeine in coffee, a popular beverage, on gastrointestinal symptoms has been the subject of ongoing debate worldwide. The …
Unraveling the link between plasma caffeine concentrations and inflammatory bow…
PMID: 38211690
Year: 2024
Relationship Type:
Association
Score: 6.5
BACKGROUND: Caffeine is believed to possess anti-inflammatory properties, yet direct population-based evidence regarding its impact on inflammatory b…
Coffee and caffeine intake reduces risk of ulcerative colitis: a case-control s…
PMID: 38073066
Year: 2024
Relationship Type:
Association
Score: 6.5
BACKGROUND AND AIM: Although diet is one of the potential environmental factors affecting ulcerative colitis (UC), evidence is not sufficient to draw…